Ken Griffin Seres Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 98,700 shares of MCRB stock, worth $80,934. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,700

Previous 36,900 167.48%

Holding current value

$80,934

Previous $28,000 153.57%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.75 - $1.56 $2,547 - $5,299	3,397 Added 313.67%	4,480 $3,000
Q4 2023 Feb 14, 2024	SELL	$0.93 - $2.15 $173,713 - $401,596	-186,789 Reduced 99.42%	1,083 $1,000
Q3 2023 Nov 14, 2023	BUY	$2.33 - $5.07 $340,410 - $740,721	146,099 Added 349.75%	187,872 $447,000
Q2 2023 Aug 14, 2023	SELL	$4.67 - $6.55 $2.28 Million - $3.2 Million	-487,920 Reduced 92.11%	41,773 $200,000
Q1 2023 May 15, 2023	BUY	$4.95 - $6.09 $2.61 Million - $3.21 Million	527,064 Added 20048.08%	529,693 $3 Million
Q4 2022 Feb 14, 2023	SELL	$5.09 - $9.05 $157,581 - $280,178	-30,959 Reduced 92.17%	2,629 $14,000
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $456,760 - $939,621	-130,503 Reduced 79.53%	33,588 $216,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.62 $196,792 - $555,391	-72,886 Reduced 30.76%	164,091 $563,000
Q1 2022 May 16, 2022	SELL	$6.3 - $8.84 $1 Million - $1.4 Million	-158,755 Reduced 40.12%	236,977 $1.69 Million
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $1.81 Million - $3.44 Million	300,526 Added 315.66%	395,732 $3.3 Million
Q3 2021 Nov 15, 2021	SELL	$5.46 - $22.6 $1 Million - $4.16 Million	-184,057 Reduced 65.91%	95,206 $663,000
Q2 2021 Aug 16, 2021	SELL	$18.46 - $24.36 $1.12 Million - $1.48 Million	-60,939 Reduced 17.91%	279,263 $6.66 Million
Q1 2021 May 17, 2021	BUY	$17.66 - $28.92 $894,143 - $1.46 Million	50,631 Added 17.48%	340,202 $7.01 Million
Q4 2020 Feb 16, 2021	BUY	$23.25 - $37.73 $5.05 Million - $8.2 Million	217,253 Added 300.41%	289,571 $7.1 Million
Q3 2020 Nov 16, 2020	BUY	$3.74 - $28.74 $149,499 - $1.15 Million	39,973 Added 123.58%	72,318 $2.05 Million
Q2 2020 Aug 14, 2020	SELL	$3.04 - $6.2 $39,164 - $79,874	-12,883 Reduced 28.48%	32,345 $154,000
Q1 2020 May 15, 2020	SELL	$2.64 - $3.82 $9,292 - $13,446	-3,520 Reduced 7.22%	45,228 $161,000
Q4 2019 Feb 14, 2020	BUY	$2.99 - $4.42 $92,244 - $136,361	30,851 Added 172.38%	48,748 $168,000
Q3 2019 Nov 14, 2019	SELL	$2.29 - $4.16 $109,329 - $198,606	-47,742 Reduced 72.73%	17,897 $71,000
Q2 2019 Aug 14, 2019	BUY	$2.28 - $7.35 $113,500 - $365,890	49,781 Added 313.92%	65,639 $212,000
Q1 2019 May 15, 2019	SELL	$4.83 - $7.21 $137,997 - $205,996	-28,571 Reduced 64.31%	15,858 $0
Q4 2018 Feb 14, 2019	BUY	$4.52 - $8.88 $58,891 - $115,697	13,029 Added 41.49%	44,429 $200,000
Q3 2018 Nov 13, 2018	BUY	$7.33 - $9.23 $74,641 - $93,989	10,183 Added 47.99%	31,400 $0
Q2 2018 Aug 10, 2018	SELL	$6.91 - $9.55 $799,535 - $1.11 Million	-115,707 Reduced 84.5%	21,217 $0
Q1 2018 May 11, 2018	SELL	$7.34 - $11.16 $5,431 - $8,258	-740 Reduced 0.54%	136,924 $1.01 Million
Q4 2017 Feb 09, 2018	BUY	$9.15 - $12.64 $1.26 Million - $1.74 Million	137,664	137,664 $1.4 Million

Others Institutions Holding MCRB

# of Institutions

Shares Held

46.7M

Call Options Held

119K

Put Options Held

466K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $102M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account